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Abstract
The growth behaviors of cutaneous neurofibromas in patients with Neurofibromatosis type 1
are highly variable. The role of the germline NF1 mutation, somatic NF1 mutation and muta-
tions at modifying loci, are poorly understood. We performed whole exome sequencing of
three growing and three non-growing neurofibromas from a single individual to assess the
role of acquired somatic mutations in neurofibroma growth behavior. 1–11 mutations were
identified in each sample, including two deleterious NF1 mutations. No trends were present
between the types of somatic mutations identified and growth behavior. Mutations in the
HIPPO signaling pathway appeared to be overrepresented.
Introduction
Neurofibromatosis type 1 (NF1), is an autosomal dominant disorder that affects approximately
one in 3500 people[1]. The underlying cause is a heterozygous mutation in the Neurofibroma-
tosis type 1 gene (NF1). Cutaneous neurofibromas (CN) are one the most frequent manifesta-
tions and a key portion of the diagnostic criteria. NF1 has considerable variability in clinical
presentation among affected individuals, within families, and even within an individual
throughout life[2]. CN can vary from a few to thousands, develop throughout life at different
rates and may or may not continue to grow once they have appeared. The genomic underpin-
nings of CN growth and development are poorly understood.
Analysis of various types of tumors in NF1 patients, including CN, have demonstrated that
independent NF1 somatic mutations likely contribute to tumorigenesis in a “second hit”
model[3]. Second hit mutations in NF1, when identifiable, appear at a distinct locus from the
germline mutation, and from other somatic NF1mutations in separate tumors within the
same individual, suggesting temporally distinct somatic events[4]. The type of mutation and
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genomic location, of both germline and somatic NF1 mutations, likely effect CN burden and
behavior. Limited genotype-phenotype correlations have been described related to the growth
behaviors of CN in NF1 for both the specific germline NF1mutation and for acquired somatic
mutations[5]. Numerous investigations have demonstrated that phenotypic expression of NF1
is likely significantly affected by the genotype at other modifying loci outside NF1, although
the role of these mutations remains unclear[6]. For example, phenotypic similarity appears to
decrease with the degree of relationship between individuals[7]. Traditionally it was believed
that all CN harbored a somatic NF1 mutation. However, only about 60% of CNs have an iden-
tifiable NF1 somatic mutation suggesting distinct somatic events outside NF1 may be sufficient
for tumorigenesis[4]. Some studies have suggested a role for microsatellite instability in NF1,
although the specific effects on growth behaviors are unclear[7].
Whether the clinical phenotypic variability of CN growth patterns correlates with the germ-
line NF1mutation type/location or the acquired somatic mutation type, location or timing,
remains unknown. This is further complicated by the fact that over 1000 different mutations
of the NF1 gene have been identified across the spectrum of substitutions, indels, splice site
alterations and gross chromosomal rearrangements, making the identification of causative
associations difficult.
The fact that multiple CNs occur in a given individual provides an ideal, internally con-
trolled, model for studying the isolated somatic events leading to CN formation and growth
patterns. In order to investigate this relationship, we performed whole exome sequencing
(WES) on six CN from a single patient and paired blood. Three of these tumors had demon-
strated clinically measurable growth in size (growing tumors), while the other three had not
changed in size during the same observation period (non-growing tumors).
Methods
This project was approved by the IRB of UCSF and was given an exempt status an exempt sta-
tus as all information was de-identified. Fresh-frozen tissue from surgically resected CNs and
matched blood were obtained from a thirty-seven year old patient under Institutional Review
Board approved protocols from University of California San Francisco. All tumor samples
were snap-frozen at the time of surgery and stored at -80 until the time of processing. Six
tumors from different body sites were selected for exome sequencing (3 growing, 3 non-grow-
ing) based on stringent quality assessment of normal and tumor DNA. Growing tumors dem-
onstrated clinically apparent growth by serial physical exam and measurement by the senior
author (MK) on 3–6 month serial exams, for greater than one year. Non-growing tumors were
similarly evaluated. Before analysis, the diagnosis of each specimen underwent central patho-
logical review and typical neurofibroma was confirmed. None of the tumors demonstrated
atypical histology or evidence of malignant peripheral nerve sheath tumor. Snap frozen tumor
tissue samples were analyzed by frozen section to assess neoplastic cellularity. Tumors were
macrodissected to enhance tumor tissue, as confirmed by serial frozen sections. DNA was
extracted using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according the manu-
facturers guidelines. Library preparation and whole exome sequencing was performed at Cen-
trillion Technologies (Palo Alto, CA) using Agilent SureSelect Human All Exon v5 (Santa
Clara, CA) on an Illumina HiSeq 2000 (San Diego, CA).
100bp paired-end reads were aligned against NCBI build 37 (hg19) of the human genome
with BWA-MEM[8]. Duplicate reads were marked, local indel realignment performed, and
base-quality scores recalibrated for each sample with the Picard suite (https://github.com/
broadinstitute/picard) and the Genome Analysis Toolkit (GATK)[9]. Novel point mutations
were identified using MuTect, while indels were identified using GATK Somatic Indel
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Detector, in tumor samples when compared against the normal[10]. Copy number segmenta-
tion was performed on log tumor/normal per-exon coverage ratios using CNVKit and the R
package ’DNAcopy’[11,12]. Visual inspection of mapped reads within the entire NF1 gene,
and all identified mutations, was performed in IGV[13].
Pathway and network analyses were performed with Ingenuity Pathway Analysis (Qiagen,
Redwood City, CA) by loading all high confidence mutations into the analysis platform with
non-modified settings.
Results
The mean depth of coverage across the seven samples was 40X-70X. Interrogation of the germ-
line sample was performed and revealed a missense mutation in NF1, f2741v. Copy number
analysis revealed no changes. Whole exome somatic mutation analysis identified 84 mutations
total (15–26 mutations per sample) (S1 Table). After visualization in IGV this was narrowed to
32 high confidence mutations (1–11 mutations per sample). The average number of mutations
per sample was five (Table 1). Two somatic mutations were found in NF1. Three mutations
were cataloged in COSMIC (http://cancer.sanger.ac.uk/cosmic): CD5,NF1 and SFN. Addition-
ally, a mutation in HLA-A was present in the COSMIC Cancer Gene Census (http://cancer.
sanger.ac.uk/census) as known to cause cancer. Canonical pathway overrepresentation analy-
sis revealed the HIPPO pathway as significantly overrepresented (p value, 2.48E-4), which
included the genes SFN, RASSF1 and DLG-4 (Fig 1). Biologic network overrepresentation anal-
ysis identified Nervous System Development and Function as the most significantly overrepre-
sented (p value 4.98E-4), which included the genes: DLG4, HFE, HLA-A, and NF1.
Discussion
Patients with NF1 characteristically develop CN. The number, age of occurrence, and the
growth rates of these tumors are highly variable among individuals and even within the same
individual. The NF1 gene encodes for the protein Neurofibromin. Neurofibromin is a negative
regulator of the Ras/mitogen-activated protein kinase (MAPK) pathway[5]. As such, NF1 is
considered a classic tumor suppressor gene and its mechanism in NF1 is felt to be consistent
with Knudson’s two-hit hypothesis in which a patient carries a mutated germline NF1 gene
copy and tumor development, including CN, then requires a second hit[14]. While the germ-
line mutations in NF1 are well cataloged, with >1000 mutations identified to date, there is a
paucity of information on the assumed acquired somatic mutations in CN[15]. This deficiency
is likely related to both the difficulty of detecting somatic mutations in CN due to cellular het-
erogeneity within the tumors and also the small number of CN analyzed. Most analyses of
somatic mutations in CN identify high confidence NF1mutations in only about half of the
tumors[4,7].
While biallelic inactivation of NF1 in CN is traditionally felt to be necessary for tumor
development, somatic mutations affecting other tumor suppressor genes, (TP53,CDKN2A and
RB1) have been identified in NF1 associated tumors including CN, suggesting that modifying
loci may be sufficient for tumor growth in the absence of a second NF1mutation, or that the
acquisition of a mutation at a modifying loci, in addition to a second NF1 hit, may be a one of
the factors affecting tumor growth behaviors[7]. Complicating this picture is the fact that the
genotype-phenotype correlation of the underlying germline mutations is poorly understood
and thus, make interpretation of all findings muddied. In order to control for this, we per-
formed WES of three growing and three non-growing CN from a single patient with NF1 to
investigate if similarities and/or differences in the types of somatic mutations between growing
and now-growing CN could be identified.
Exome Sequencing of Cutaneous Neurofibromas
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It has been hypothesized that certain germline NF1 mutations may predispose to particular
phenotypes. For example, germline splice site mutations in NF1may increase the risk of tumor
development[16]. Similarly, full NF1 deletion is associated with early appearance and higher
burden of CN[17], while a 3-bp in-frame deletion of Exon 17 is associated with fewer CN[18].
Therefore, as a first step, we interrogated the germline to identify the germline NF1 muta-
tion in this individual. A single missense mutation, f2741v was identified. While this mutation
does not appear in COSMIC or cBioPortal (www.cbioportal.org), a frameshift insertion at the
same location has been reported. Copy number analysis did not reveal any copy number
variants.
Thirty-two high confidence somatic mutations were identified in the six samples. The only
recurrently mutated gene was NF1, which contained two deleterious mutations: a stop gain
(Growing 3) and an in frame deletion (Non-growing 1). Two other mutations in separate
samples were also cataloged in COSMIC: CD5 (Growing 1) and SFN (Non-growing 3). CD5
Table 1. Somatic Mutations in Growing and Non-growing Neurofibromas.
Samples
Growing 1 Growing 2 Growing 3 Non-Growing 1 Non-Growing 2 Non-Growing 3 Variant classification
RASSF1 x synonymous
TRAV9-1 x missense
SUDS3 x missense
KLHL20 x frameshift
CD5 x missense_variant
DLG4 x missense_variant
WIBG x missense_variant
UNC5CL x missense_variant
HFE x missense_variant
HECW1 x missense_variant
VPS36 x synonymous
COL22A1 x synonymous
UBASH3A x missense
CYFIP2 x missense
PTPRZ1 x sequence
RYR1 x synonymous
NF1 x stop gained
NF1 x disruptive inframe deletion
DCAF13 x missense
PSD2 x missense
SLC25A14 x synonymous, splice region
NIPBL x missense
ITIH1 x missense
INA x missense
PRTG x missense
TTC28 x missense
EIF4G1 x missense, splice region
ABCC3 x synonymous
SFN x synonymous
CYP17A1 x missense
NOA1 x missense
HLA-A x missense
doi:10.1371/journal.pone.0170348.t001
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encodes a transmembrane glycoprotein that belongs to the highly conserved scavenger-receptor
cysteine-rich superfamily. CD5 is felt to regulate antitumor immune response by potentiating
tumor-specific T-cell reactivity[19]. The mutation at CD5 is a missense mutation, Ser485Cys,
also reported in lung cancer (http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=
689345). The SFN (Stratifin) gene encodes for the 14-3-3σ protein. The 14-3-3σ protein regu-
lates numerous cellular processes that are important in cancer biology, including apoptosis and
Fig 1. HIPPO Signaling Pathway. Components of HIPPO signaling pathway. Magenta circles represent genes/gene products mutated in NF1 tumors. 14-3-
3 protein is encoded by SFN gene.
doi:10.1371/journal.pone.0170348.g001
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cell-cycle checkpoints[20]. The mutation at SFN is a silent mutation, Cys96Cys, also reported in
biliary tract cancer (http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=5511476).
In addition to the mutations present in COSMIC, the gene HLA-A (major histocompatibil-
ity complex; class I; A) is present in the COSMIC Cancer Gene Census, which is a catalog of
genes causally implicated in cancer. Loss of HLA class I antigens has been reported to be mecha-
nism by which tumor cells escape immune attack[21]. The HLA-A mutation is a missense
mutation, Lys292Glu. Four additional genes with mutations in our cohort have been reported
to play a role in tumorigenesis in the literature: TTC28,COL22A1,DLG4 and RASSF1.TTC28 is
a target of TP53 and is reported to inhibit tumor cell growth[22]. COL22A1 has been identified
as a recurrently mutated gene in lung cancer[23]. DLG4 has been suggested to function as a
tumor suppressor and is involved in the development of HPV related cancers[24]. RASSF1 is a
recognized tumor suppressor. RASSF1 promoter methylation is one of the most frequent alter-
ations found in human tumors[25]. Lastly a missense mutation in PRTG was of interest as it has
a known role in neurogenesis[26].
In order to investigate if any pathways were overrepresented in our gene sets we performed
a canonical pathway overrepresentation analyses using Ingenuity Pathway Analysis. Interest-
ingly, HIPPO signaling was identified as the single highly overrepresented pathway. The SFN,
RASSF1 and DLG-5 gene products exist with this signaling cascade. HIPPO signaling is known
to regulate cell cycle progression, apoptosis and cell differentiation[27]. Dysregulation of the
HIPPO pathway is felt to contribute to cancer development through tumor initiation and pro-
gression and has considerable cross-talk with the WNT, SMAD and NOTCH pathways[27–
29]. Dysregulation of the HIPPO signaling cascade has not previously been reported in NF1
and warrants further investigation.
One existing hypothesis regarding growth and arrest of CN is that NF1mutation triggers
activation of Ras which then leads to oncogene induced senescence[30]. Additional mutations
are then necessary for escape from this senescence, arguing in favor of modifying genes as a
factor that could account for variable growth behaviors. This feedback cycle involves a number
of genes as reviewed by Courtois-cox et al[30]. No mutations were identified in these senes-
cence pathways. Further investigation of the transcriptome and epigenetic modifications of
growing and non-growing CN may help further investigate this hypothesis.
While our study generates a number of interesting hypotheses for further investigation, there
are a number of limitations. First, while our samples were separated into growing and non-
growing by serial physical exam by a single author, a more objective measurement of growth
was not obtained as the study was conducted in a retrospective fashion. The lack of an objective
measurement of growth could account for a portion of the difficult in identifying a unifying
theme among growing or non-growing CNs. Second, the fact that only 33% of the tumors had
identifiable mutations in NF1, despite good coverage at the NF1 locus, may reflect the known
difficulty in identifying somatic NF1mutations due to cellular heterogeneity, or may reflect the
concept that mutations at modifying loci may be sufficient for CN growth and account for dif-
ferences in CN growth behavior. All samples appear to have a mutation in at least one gene that
could potentially be causative; however, whether these mutations are passenger or drivers is
unclear. There were no identifiable trends regarding the number of mutations or types of muta-
tions within or between growing and non-growing samples as hypothesized. Additional studies
with larger cohorts are needed to further investigate this question.
Conclusions
CN growth behavior in NF1 is poorly understood due to the multitude of variables potentially
effecting tumor development and growth. Here we performed WES on three growing and
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three non-growing CN from a single individual to test the hypothesis that somatic mutations
in modifying loci could account for differences in growth behaviors between growing and
non-growing CN. We identified between 1–11 mutations per samples with deleterious NF1
mutations in two samples. While provocative mutations were identified in each of the samples
at potential modifying loci, no trends were identified between mutations and in growing and
non-growing samples. Mutations in genes in the HIPPO pathway appeared to be over-repre-
sented. Additional studies of the exome and transcriptome, as well as epigenetic modifications,
in larger cohorts of growing and non-growing CN, are needed.
Supporting Information
S1 Table. Somatic mutations. All identified somatic mutations. Highlighted samples are high
confidence.
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